Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study

Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawal of aspirin has emerged as a bleeding reduction strategy,...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JACC Basic Transl Sci
Päätekijät: Franchi, Francesco, Rollini, Fabiana, Kairouz, Victor, Rivas Rios, Jose, Rivas, Andrea, Agarwal, Malhar, Briceno, Maryuri, Wali, Mustafa, Nawaz, Ahmed, Silva, Gabriel, Shaikh, Zubair, Maaliki, Naji, Been, Latonya, Piraino, Jason, Pineda, Andres M., Suryadevara, Siva, Soffer, Daniel, Zenni, Martin M., Jennings, Lisa K., Bass, Theodore A., Angiolillo, Dominick J.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2019
Aiheet:
CLINICAL RESEARCH
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6978557/
https://ncbi.nlm.nih.gov/pubmed/31998847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2019.07.011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia